Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
Vanda Pharmaceuticals Q2 Earnings Call Highlights
Vanda Pharmaceuticals NASDAQ: VNDA reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic competition and shipment timing. The company reiterated its full-year revenue outlook and said it expects operating expenses to begin declining late this year, with more substantial reductions anticipated in 2027.
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago.
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss
Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeline, and strong top-line growth potential. VNDA's near-zero debt and undervalued price/book ratio offer balance sheet strength and significant upside, with Wall St. forecasting considerable price appreciation as of Tuesday's data. Earnings and cash flow trends remain weak, with persistent operating losses, high R&D costs, and no profitability expected until at least 2030.
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
The mean of analysts' price targets for Vanda (VNDA) points to a 105% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation
Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy
Vanda Pharmaceuticals Inc. has received FDA approval for BYSANTI, a new atypical antipsychotic targeting bipolar I disorder and schizophrenia. VNDA now markets five products, but BYSANTI's differentiation from Fanapt is questioned due to similar active molecules and looming patent expiry. 2025 saw Fanapt sales up 24%, but VNDA posted a $(220.5m) net loss and expects higher cash burn in 2026, raising funding concerns.
Vanda Pharmaceuticals stock's explosive rally may be more hype than substance
Vanda Pharmaceuticals (NASDAQ: VNDA) opened some 45% higher today after the biotech firm said it has received the FDA's approval for its treatment of schizophrenia and bipolar I disorder. The BYSANTI (milsaperidone) announcement is a welcome reprieve for VNDA that's been under pressure this year as investors weighed “disappointing” Q4 earnings against a backdrop of clinical uncertainty.
Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week
Vanda Pharmaceuticals reported weak FY25 results, with a GAAP EPS miss and heavy losses, despite 9% revenue growth driven by Fanapt. VNDA's valuation is deeply discounted, trading at 1.4x forward sales and 0.5x EV/sales, reflecting high regulatory and execution risk. Upcoming catalysts include the Nereus launch and Bysanti's PDUFA decision; approval could diversify revenues but is far from guaranteed.
Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript
